Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 plus boosted darunavir vs placebo in virologically suppressed HIV
2015-004195-30Phase 2Completed
- Sponsor
- Abivax
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) comparing ABX464 plus boosted darunavir with Placebo plus boosted darunavir (2 arms). Primary endpoint: Safety (adverse events). Started Dec 2015; status: completed.
02
Drugs
obefazimod
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on 2015-004195-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004195-30.